Overall survival (OS) and forced vital capacity (FVC) results from the LUME-Meso study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) vs placebo (P) + PEM/CIS in chemo-naïve patients (pts) with malignant pleural mesothelioma (MPM)Silvia Novello, Giorgio V. Scagliotti, Anna K. Nowak et al.|Annals of Oncology|2017Cited by 0